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ORIGINAL RESEARCH
Association of Pro- B- Type Natriuretic 
Peptide With Cardiac Magnetic 
Resonance– Measured Global and Regional 
Cardiac Function and Structure Over 
10 Years: The MESA Study
Amir Ali Rahsepar , MD; David A. Bluemke , MD, PhD; Mohammadali Habibi, MD; Kiang Liu, PhD; 
Nadine Kawel- Boehm , MD; Bharath Ambale- Venkatesh, PhD; Veronica R. S. Fernandes, MD; Boaz D. Rosen, MD; 
Joao A. C. Lima , MD; James C. Carr, MD
BACKGROUND: NT- proBNP (N- terminal pro- B- type natriuretic peptide) is widely used to diagnose and manage patients with 
heart failure. We aimed to investigate associations between NT- proBNP levels and development of global and regional myo-
cardial impairment, dyssynchrony, and risk of developing myocardial scar over time.
METHODS AND RESULTS: We included 2416 adults (45– 84 years) without baseline clinical cardiovascular disease from MESA 
(Multi- Ethnic Study of Atherosclerosis). NT- proBNP was assessed at baseline (2000– 2002). Cardiac magnetic resonance– 
measured left ventricular parameters were assessed at baseline and year 10 (2010– 2012). Tagged cardiac magnetic reso-
nance and myocardial dyssynchrony were assessed. We used linear and logistic regression models to study the relationships 
between quartiles of NT- proBNP levels and outcome variables. Left ventricular parameters decreased over time. After 10- year 
follow- up and adjusting for cardiovascular disease risk factors, people in the highest quartile had significantly greater decline 
in left ventricular ejection fraction (−1.60%; 95% CI, −2.26 to −0.94; P<0.01) and smaller decline in left ventricular end systolic 
volume index (−0.47 mL/m2; 95% CI, −1.18 to 0.23; P<0.01) compared with those in the lowest quartile. Individuals in the high-
est quartile had more severe risk factor adjusted global, mid, and apical regional dyssynchrony compared with those in the 
lowest, second, and third quartiles (all P- trend<0.05). Compared with the lowest- quartile group, the adjusted odds ratios for 
having myocardial scar was 1.3 (95% CI, 0.7– 2.2) for quartile 2; 1.2 (95% CI, 0.6– 2.3) for quartile 3; and 2.7 (95% CI, 1.4– 5.5) 
for quartile 4 (P- trend=0.012) for the total sample.
CONCLUSIONS: Among participants without baseline clinical cardiovascular disease, higher baseline NT- proBNP concentration 
was significantly associated with subclinical changes in developing myocardial dysfunction, more severe cardiac dyssyn-
chrony, and higher odds of having myocardial scar over a 10- year period independent of traditional cardiovascular disease 
risk factors.
Key Words: cardiac magnetic resonance imaging ■ longitudinal study ■ NT- proBNP ■ scar
Elevated NT- proBNP (N- terminal pro- B- type na-triuretic peptide) levels are associated with many cardiovascular pathologies, including heart failure, atrial fibrillation, and stroke, and they have also been linked to preclinical states of vascular damage and reduced myocardial perfusion.1,2 Moreover, it was 
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previously reported in the MESA (Multi- Ethnic Study of 
Atherosclerosis) participants that elevated NT- proBNP 
is associated with increment in extracellular volume 
fraction and native T1 value, imaging markers of micro-
scopic fibrosis.3
Cardiac magnetic resonance (CMR) imaging is 
the current reference standard for the assessment 
of myocardial structure and function.4 CMR with 
myocardial tissue tagging provides quantitative and 
highly reproducible myocardial data that are largely 
operator and patient independent, as well as charac-
terization of myocardial scar and scar distribution.5,6 
In addition to myocardial strain, myocardial dyssyn-
chrony is another index of regional myocardial con-
tractility dysfunction. CMR is also able to accurately 
evaluate myocardial tissue for presence of scar. In 
the MESA study, prevalence of myocardial scar was 
reported to be 7.9% at year 10 among participants 
who were free of clinical CVD at the time of enroll-
ment, while 78% of these participants were unrecog-
nized by ECG or clinical adjudication.7
To date, few studies have evaluated the direct rela-
tionship of NT- proBNP levels at baseline to changes in 
CMR- measured myocardial structure/function, dyssyn-
chrony, and myocardial scarring over time, and data are 
even more scarce for large, ethnically diverse prospec-
tive cohorts. Therefore, the purpose of this study is to 
investigate the potential mechanisms and implications 
behind the associations between NT- proBNP levels at 
baseline and changes in global and regional myocar-
dial function, dyssynchrony, development of myocardial 
scar tissue, and extent of scar burden during 10- year 
follow- up using data collected from the MESA study.
METHODS
Data Availability Statement
The MESA cohort participates in the National Heart, 
Lung, and Blood Institute’s Biologic Specimen and Data 
Repository. The MESA data are available upon request, 
including data from examinations 1 to 5 used in this anal-
ysis. Requests for data can be made through the follow-
ing Web site: https://bioli ncc.nhlbi.nih.gov/studi es/mesa/.
Study Sample
The design of MESA has been described in detail previ-
ously.8 Briefly, MESA is a multicenter, population- based 
cohort study of 6 communities in the United States 
(Illinois, North Carolina, Maryland, California, New 
York, and Minnesota). Participants were recruited be-
tween July 2000 and August 2002. Participants defined 
themselves as White (38%), African- American (28%), 
Hispanic (22%), or Chinese American (12%). All MESA 
participants were free of clinical cardiovascular disease 
(CVD) at baseline. The MESA study was approved by 
the institutional review boards of all participating cent-
ers, and all participants gave written, informed consent. 
For the present study, we included 2416 MESA partici-
pants who had plasma NT- proBNP measured at base-
line, underwent CMR imaging, had CMR measures of 
left ventricular (LV) parameters at baseline and year 
10 (2010– 2012, follow- up), and had no missing data 
on covariates of interest. Sample sizes varied for each 
outcome studied and are as follows: baseline LV pa-
rameters, n=2416; change in LV parameters over time, 
n=2416; LV dyssynchrony/strain parameters at follow-
 up, n=2211; presence of late gadolinium enhancement 
imaging during follow- up, n=1498 (Figure).
Assessment of NT- proBNP
Serum NT- proBNP levels were measured at the core 
lab (University of California, San Diego) using a highly 
CLINICAL PERSPECTIVE
What Is New?
• NT- proBNP (N- terminal pro- B- type natriuretic 
peptide) is a marker of cardiac remodeling and 
is widely used to diagnose and manage patients 
with heart failure.
• We investigated the association of NT- proBNP 
levels; markers of cardiac remodeling and heart 
failure; and development of global and regional 
myocardial impairment, dyssynchrony, and risk 
of developing myocardial scar over 10 years.
• After 10- year follow- up and adjusting for car-
diovascular disease risk factors, higher levels of 
NT- proBNP were significantly associated with 
reduced left ventricular ejection fraction; more 
severe global, mid, and apical regional dyssyn-
chrony; and higher risk of having myocardial 
scar.
What Are the Clinical Implications?
• Our findings lend support to consider earlier 
screening using biomarkers such as NT- proBNP 
in identifying persons with subclinical cardiovas-
cular disease who may benefit most from early 
therapeutic intervention and provide measures 
for cardiovascular disease prevention.
Nonstandard Abbreviations and Acronyms
ECC circumferential strain
MESA Multi- Ethnic Study of Atherosclerosis
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sensitive and specific Elecsys electrochemilumines-
cence immunoassay based on the double- antibody 
sandwich method (Roche Diagnostics Corporation, 
Indianapolis, IN), as previously described.9 A previously 
unthawed or only thawed once 250- μL serum sample 
was used for analysis. The intra- and interassay coef-
ficients of variation were as follows: at 175 pg/mL, 2.7% 
and 3.2%; at 355 pg/mL, 2.4% and 2.9%; at 1068 pg/
mL, 1.9% and 2.6%; and at 4962  pg/mL, 1.8% and 
2.3%, respectively.10
Assessment of Cardiovascular Risk 
Factors
All participants underwent comprehensive baseline 
testing including documentation of comorbidities; 
measurement of heart rate and blood pressure; lab-
oratory testing (including fasting glucose and fast-
ing lipid profile); and computed tomography of the 
chest for the determination of coronary artery cal-
cium (CAC) score. Body mass index was calculated 
as weight divided by the square of height (kg/m2). 
Blood pressure at rest was measured 3 times in the 
seated position, and the last 2 measurements were 
averaged and used for these analyses. Hypertension 
was defined as systolic blood pressure ≥140 mm Hg, 
diastolic blood pressure ≥90 mm Hg, or current use 
of antihypertensive medications. Diabetes mellitus 
was defined as fasting glucose ≥126  mg/dL or the 
use of diabetic medications. Physical activity was 
defined as the number of metabolic equivalent min-
utes per week spent doing intentional leisure- time 
exercise (eg, moderate walking exercise, dance, and 
vigorous sports). Computed tomography scanning 
(for CAC) in MESA have been described in detail pre-
viously.11 For the present study, we included data on 
CAC score as a marker of subclinical atherosclerosis 
at baseline.
Assessment of LV Structure and Function
The MESA CMR protocol has been described in 
detail previously.12 Briefly, CMR examinations were 
performed at 6 MESA field centers using 1.5- Tesla 
scanners. All images were read at the central MESA 
CMR review center at Johns Hopkins University 
(Baltimore, MD). LV mass, LV end- diastolic and LV 
end- systolic volumes, and LV ejection fraction (LVEF) 
were calculated by drawing endocardial and epicar-
dial contours at end systole and end diastole on the 
short- axis stack of slices in each subject. The papillary 
muscle mass was excluded from LV mass. LV mass 
and volume index were defined as LV mass and vol-
ume divided by body surface area. A detailed explana-
tion of the development and application of calibration 
curves between the baseline and follow- up exams are 
presented in Data S1.13
Assessment of Myocardial Strain, 
Dyssynchrony, and Scar
Strain analysis has been described in detail previ-
ously.14 Peak systolic circumferential strain (ECC) 
was measured using the HARP method embedded 
in MATLAB software (HARP 1.15, Diagnosoft, Palo 
Alto, CA).15 ECC regional strain was determined at 3 
levels (basal, mid, and apical) for 4 LV regions (sep-
tum, anterior, posterior, and lateral), expressed as a 
percentage, with negative values representing cir-
cumferential shortening. Peak “global” systolic strain 
was calculated as the averaged peak ECC across 
all 12 segments. Indexes of cardiac dyssynchrony 
were derived from CMR strains. Time to peak systole 
(TPS) was defined as time intervals from end diastole 
to peak systolic circumferential strain. SD of time to 
peak systolic strain across all 12 segments was used 
as the index of global myocardial dyssynchrony, as 
previously described by Rosen et al.6 Higher SD of 
TPS means greater myocardial dyssynchrony.
Late gadolinium enhancement– CMR imaging was 
performed 15  minutes after intravenous contrast- 
agent administration (Magnevist; Bayer Healthcare 
Pharmaceuticals, Wayne, NJ) at a dose of 0.15- mmol/
kg using inversion- recovery fast gradient- echo pulse 
sequences. Scar measurements were performed 
using Qmass (version 7.2; Medis, Leiden University 
Medical Center, Leiden, Netherlands) using a semi- 
automated technique, as previously described.16 
Myocardial scars were classified as either ischemic 
(involving the subendocardium in a coronary artery 
distribution) or nonischemic (predominantly midwall 
or subepicardium location without subendocardial 
involvement in a noncoronary distribution).7 The ex-
tent of scarring was quantified as a percentage of LV 
mass.
Statistical Analysis
Baseline and year 10 data for the CMR- derived LV 
parameters and major cardiovascular risk factors 
were computed for the study sample, with results 
expressed as the mean (SD) for normally distrib-
uted continuous variables, the median (interquartile 
range) for nonnormally distributed continuous vari-
ables, and the counts and percentages for categori-
cal variables. Differences in mean values between 
baseline and year 10 data were compared using 
paired t- tests. When departures from normality were 
detected in the continuous variables, differences in 
distributions were compared with the Wilcoxon rank- 
sum test. Differences in proportions for the categori-
cal variables were compared using the chi- square or 
McNemar test.
Participants were classified into 4 NT- proBNP 




 http://ahajournals.org by on A
pril 8, 2021
J Am Heart Assoc. 2021;10:e019243. DOI: 10.1161/JAHA.120.019243 4
Rahsepar et al NT- proBNP and Cardiac Disease
distribution within the entire cohort (Q1 [low], 5 to 
<24 pg/mL; Q2, 24 to <55 pg/mL; Q3, 55 to <112 pg/
mL; Q4 [high], ≥112 pg/mL). NT- proBNP values were 
log- transformed using the base- 10 log (log) before 
modeling as a continuous variable (because of highly 
skewed distribution). General linear models were 
used to compute NT- proBNP group mean values 
and 95% CIs for each LV structure/function measure 
at baseline and changes in these parameters over 
10 years, LV global and regional myocardial function 
at year 10, and extent of dyssynchrony at year 10. 
Multivariable logistic regression analyses were used 
to model the odds for developing scar at 10- year fol-
low- up using NT- proBNP categorically (included in 
the models as 3 dummy variables, with the lowest 
quartile as the omitted reference group). Standard 
techniques were used to select models and to test 
for model validity (eg, goodness of fit, interactions, 
and collinearity).17 There was no evidence of nonlin-
earity in the relationship between log (NT- proBNP) 
and the log odds of myocardial scar. The Hosmer– 
Lemeshow statistical test for goodness of fit was 
also considered and found to be nonsignificant. Test 
for linear trend was performed with the continuous 
log (NT- proBNP) in appropriate models (ie, general 
linear models for continuous outcomes and logistic 
regression for binary outcomes).
Covariates identified a priori on the basis of pre-
viously published NT- proBNP and subclinical CVD 
studies were screened for inclusion into the multivari-
able models. The final model included race/ethnicity 
(included as 4 indicator variables with White people 
as the omitted reference group), sex, and baseline 
variables: age (per year), education more than high 
school, physical activity (sex- specific tertiles: low, 
middle, high), current cigarette smoking, diabetes 
mellitus, body mass index, systolic blood pressure, 
antihypertensive medication use, high- density lipo-
protein cholesterol, total cholesterol, statin medica-
tion use, prevalence of CAC score >10, LV parameter 
outcome of interest (in models of LV change only), 
and LV mass (in models for global and regional LV 
strain and dyssynchrony only). In addition, effect 
modification by sex was examined by including inter-
action term between log (NT- proBNP) with sex, ad-
justed for age. For models with significant interaction 
terms, the regression analysis was repeated sepa-
rately by stratifying sex. The potential for effect mod-
ification by race/ethnicity with NT- proBNP was not 
investigated because of the small number of Chinese 
people in the NT- proBNP highest quartile.
The Shapiro– Wilk test or Q- Q plot was used to 
check for normality of distribution for the CMR out-
comes in relation to log (NT- proBNP), and no depar-
tures from normality were found. Variance inflation 
factors were also calculated for the independent 
variable (log [NT- proBNP]), and all aforementioned 
covariates and found to be all <1.7, indicating no ex-
cessive multicollinearity in our data that warranted 
any corrective measures. All analyses were con-
ducted using SAS statistical software version 9.4 
(SAS Institute Inc, Cary, NC). The statistical testing 




Among 6814 MESA participants at baseline, 4091 
had both NT- proBNP and CMR measures of LV pa-
rameters, 1675 were excluded because of missing 
data or were lost to follow- up. According to base-
line data, the cohort of individuals (n=2416) included 
in this analysis was more likely to be younger and 
healthier, with lower NT- proBNP levels, lower rates 
of CAC score >10, lower values for systolic blood 
pressure, less diabetes mellitus, and lower rates of 
antihypertensive medication use; a higher propor-
tion of White participants and a lower proportion of 
Hispanic participants; and also more commonly non-
smokers, more educated, and participated in more 
physical activity than individuals who were excluded 
in the study (Table S1).
Our study sample included 2416 MESA participants 
(51.1% women; 43% White, 22% African- American, 
21% Hispanic, and 14% Chinese) with a mean age 
of 59.6  years, and the median (interquartile range) 
NT- proBNP was 46.9 (20.5– 91.9) pg/mL at baseline. 
The characteristics of the participants at baseline and 
year 10 are displayed in Table 1. Participants at year 
10 were more likely to be taking antihypertensive or 
lipid- lowering therapies, increased heart rate, and 
higher prevalence of diabetes mellitus. However, body 
mass index was similar between baseline and year 10. 
Increase in LV mass index and decrease in LV volume 
indices were observed at year 10.
The log (NT- proBNP) level had significant positive 
correlations with baseline risk factors: age, high phys-
ical activity, systolic blood pressure, antihypertensive 
medication use, high- density lipoprotein cholesterol, 
and CAC score >10. Significant negative correlations of 
the log (NT- proBNP) level were observed for baseline 
risk factors: sex, race/ethnicity, education more than 
high school, body mass index, current smoking, and 
diabetes mellitus (Table S2).
Baseline NT- proBNP and LV Structure 
and Function
Higher levels of NT- proBNP were positively and signif-
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mean values for the baseline LV mass index, end- 
diastolic volume index, end- systolic volume index, 
and stroke volume index (all P- trend<0.001), but 
not with ejection fraction or cardiac output (Table 2, 
model 2).
Among participants who completed both CMRs at 
baseline and year 10, LV end- diastolic volume index 
decreased, end- systolic volume index decreased, 
stroke volume index decreased, ejection fraction de-
creased, and mass index increased over time (Table 3). 
Compared with the lowest quartile group, individuals 
in the highest NT- proBNP quartile had a smaller risk 
factor– adjusted decline in LV end- systolic volume index 
(−0.47 mL/m2; 95% CI, −1.18 to 0.23; P<0.01), and a 
greater decline in LV ejection fraction (−1.60%; 95% CI, 
−2.26 to −0.94; P<0.01) over time. No significant as-
sociations were noted between baseline NT- proBNP 
levels and changes in LV mass, end- diastolic volume, 
stroke volume, and cardiac output over time (model 
2). In addition, there was no significant interaction be-
tween baseline NT- proBNP levels and sex in relation to 
the association of any of the baseline LV parameters 
and 10- year change in each LV parameter, adjusted for 
age (all P for interaction >0.05).
Table 1. Participant Characteristics at Baseline and Year 10, the MESA Study (2001– 2011)
N=2416 Baseline Year 10 P Value*
Age, mean (SD), y 59.6 (9.3)
Women, n (%) 2470 (51.1)
Race/ethnicity, n (%)
White 1043 (43.2)
African- American 532 (22.0)
Hispanic 510 (21.1)
Chinese 331 (13.7)
NT- proBNP, pg/mL, median (IQR) 46.9 (20.5– 91.9)
Education > HS graduate, n (%) 1723 (71.3)
BMI, kg/m2, mean (SD) 27.6 (4.9) 27.8 (5.1) 0.119
Smoking status, n (%)
Never 1283 (53.1) 1135 (47.0) <0.001
Former 867 (35.9) 1108 (45.8)
Current 226 (11.0) 173 (7.2)
Physical activity,† MET- min/wk, median (IQR) 945.0 (210.0– 2100.0) 1710.0 (720.0– 3540.0) <0.001
Systolic BP, mm Hg, mean (SD) 122.9 (20.0) 122.3 (20.0) 0.305
Diastolic BP, mm Hg, mean (SD) 71.7 (10.2) 68.0 (9.9) <0.001
Heart rate, beats/min, mean (SD) 62.3 (9.1) 66.6 (21.3) <0.001
Antihypertensive medication, n (%) 739 (30.6) 1267 (52.4) <0.001
Diabetes mellitus, n (%) 201 (8.3) 390 (16.1) <0.001
HDL- C cholesterol, mg/dL, mean (SD) 51.3 (14.8) 55.9 (16.7) <0.001
Total cholesterol, mg/dL, mean (SD) 193.6 (33.9) 183.6 (36.8) <0.001
Statin medication, n (%) 326 (13.5) 858 (35.5) <0.001
CAC score >10, Agatston units, n (%) 863 (36)
Left ventricle, mean (SD)
End- diastolic mass index, g/m2 64.2 (11.2) 66.3 (13.7) <0.001
End- diastolic volume index, mL/m2 69.9 (12.1) 64.9 (14.1) <0.001
End- systolic volume index, mL/m2 26.1 (6.4) 24.9 (8.7) <0.001
Stroke volume index, mL/m2 43.8 (8.4) 40.0 (8.6) <0.001
Ejection fraction, n % 62.7 (5.8) 62.0 (7.3) <0.001
Cardiac output, L/min, mean (SD) 5.3 (1.4) 4.8 (1.7) <0.001
Results are expressed as mean (SD), number (%), or median (IQR). All LV volume and mass measurements were adjusted for body surface area. BMI indicates 
body mass index; BP, blood pressure; CAC, coronary artery calcium; HDL, high- density lipoprotein; HS, high school; IQR, interquartile range (Q1– Q3); MESA, 
Multi- Ethnic Study of Atherosclerosis; MET, metabolic equivalent of task; and NT- proBNP, N- terminal pro- B- type natriuretic peptide.
*P values for test of difference between baseline and year 10; paired t- test for continuous variables; chi- square or McNemar for categorical variables; or 
Wilcoxon rank- sum test for nonparametric variables.
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Baseline NT- proBNP and Subsequent LV 
Strain, Dyssynchrony, Myocardial Scar 
and Scar Extent
Table 4 shows the adjusted mean values of year 10 LV 
strain and dyssynchrony parameters at the global and 
regional (basal, mid, and apical) levels in relation to NT- 
proBNP quartiles. Higher levels of NT- proBNP were 
independently associated with higher subsequent risk 
factor– adjusted mean SD of TPS at the global (3.9 ms; 
95% CI, 3.8– 4.0; P- trend=0.016), mid and apical re-
gions (P- trend=0.043 and 0.041, respectively), as well 
as higher ECC at the basal region (P- trend=0.014). 
The associations between NT- proBNP levels and the 
other ECC regions were largely nonsignificant.
In this sample, the overall prevalence of CMR- 
defined myocardial scar at year 10 was 7.5% (113/1498; 
Table  5). Table  5 presents the odds ratios and 95% 
CIs of developing myocardial scar for the total group 
and by women and men separately over 10- year fol-
low- up periods, adjusted for baseline cardiovascular 
risk factors. In age- , race- , and sex- adjusted analyses 
for the total sample, the odds ratio of developing scar 
at year 10 for individuals in the highest quartile was 2.9 
(95% CI, 1.5– 5.6) versus the lowest quartile (Table 5, 
model 1). Adjustment for baseline CVD risk factors 
only slightly attenuated the results (model 2). For the 
total sample, the association of NT- proBNP levels with 
risk of myocardial scar was positive, significant, and 
graded (P- trend=0.012; Table 5, model 2).
Table 2. Baseline Left Ventricular Structure/Function in Relation to NT- proBNP Quartiles (N=2416)
Models*
NT- proBNP Quartiles (pg/mL)
P Trend†
Q1 (Low, 5 to <24) 
N=704
Q2 (24 to <55) 
N=648
Q3 (55 to <112) 
N=608
Q4 (High, ≥112) 
N=456
Mean (95% CI)
LV end- diastolic mass index, g/m2
Unadjusted 65.5 (64.7– 66.4) 64.2 (63.4– 65.1) 62.8 (61.9– 63.7) 64.0 (63.0– 65.0)‡ 0.001
Model 1 62.3 (61.5– 63.1) 64.0 (63.3– 64.8) 64.3 (63.5– 65.0) 67.4 (66.4– 68.3)‖ <0.001
Model 2 63.1 (62.3– 63.8) 64.1 (63.4– 64.8) 64.1 (63.4– 64.9) 66.2 (65.3– 67.2)‖ <0.001
LV end- diastolic volume index, mL/m2
Unadjusted 68.9 (68.0– 69.8) 69.5 (68.5– 70.4) 69.7 (68.7– 70.6) 72.2 (71.1– 73.3)‖ <0.001
Model 1 67.3 (66.4– 68.2) 69.3 (68.5– 70.2) 70.3 (69.4– 71.2) 74.0 (72.8– 75.1)‖ <0.001
Model 2 67.9 (67.0– 68.8) 69.4 (68.6– 70.3) 70.2 (69.3– 71.1) 73.1 (72.0– 74.2)‖ <0.001
LV end- systolic volume index, mL/m2
Unadjusted 26.8 (26.4– 27.3) 26.0 (25.5– 26.5) 25.5 (25.0– 26.0) 25.8 (25.3– 26.4)§ 0.010
Model 1 25.3 (24.8– 25.7) 25.8 (25.4– 26.3) 26.2 (25.7– 26.6) 27.7 (27.1– 28.3)‖ <0.001
Model 2 25.5 (25.0– 26.0) 25.9 (25.4– 26.3) 26.1 (25.6– 26.6) 27.4 (26.8– 28.0)‖ <0.001
LV stroke volume index, mL/m2
Unadjusted 42.6 (42.0– 43.3) 43.5 (42.9– 44.2) 44.0 (43.3– 44.6) 45.6 (44.8– 46.4)‖ <0.001
Model 1 42.0 (41.4– 42.7) 43.5 (42.9– 44.1) 44.2 (43.5– 44.8) 46.3 (45.5– 47.1)‖ <0.001
Model 2 42.4 (41.8– 43.1) 43.6 (42.9– 44.2) 44.1 (43.4– 44.7) 45.7 (44.9– 46.5)‖ <0.001
LV ejection fraction, %
Unadjusted 61.8 (61.4– 62.2) 62.6 (62.2– 63.1) 63.1 (62.6– 63.5) 63.4 (62.9– 63.9)‖ <0.001
Model 1 62.3 (61.9– 62.8) 62.7 (62.3– 63.1) 62.8 (62.4– 63.3) 62.9 (62.3– 63.4) 0.525
Model 2 62.4 (61.9– 62.8) 62.7 (62.3– 63.1) 62.8 (62.3– 63.2) 62.8 (62.3– 63.4) 0.783
Cardiac output, L/min
Unadjusted 5.5 (5.4– 5.6) 5.4 (5.3– 5.5) 5.1 (5.0– 5.2) 5.1 (5.0– 5.2)‖ <0.001
Model 1 5.3 (5.2– 5.4) 5.4 (5.3– 5.5) 5.2 (5.1– 5.3) 5.4 (5.3– 5.5) 0.911
Model 2 5.3 (5.2– 5.4) 5.4 (5.3– 5.5) 5.2 (5.1– 5.3) 5.4 (5.2– 5.5) 0.825
All LV volume and mass measurements were adjusted for body surface area. CAC indicates coronary artery calcium; LV, left ventricular; and NT- proBNP, 
N- terminal pro- B- type natriuretic peptide.
*Model 1: adjusted for age, sex, and race (White [reference], African- American, Chinese, Hispanic); Model 2: adjusted for all variables in model 1 plus 
education more than high school, physical activity (sex- specific tertiles: low, middle, high), current cigarette smoking, diabetes mellitus, body mass index, 
systolic blood pressure, antihypertensive medication use, high- density lipoprotein cholesterol, total cholesterol, statin medication use, and prevalence of CAC 
score >10.
†P for linear trend tested by entering log (NT- proBNP) as a continuous variable in the same model.




 http://ahajournals.org by on A
pril 8, 2021
J Am Heart Assoc. 2021;10:e019243. DOI: 10.1161/JAHA.120.019243 7
Rahsepar et al NT- proBNP and Cardiac Disease
Significant interaction was observed between 
baseline NT- proBNP levels and sex for risk of myo-
cardial scar during the 10- year follow- up period (P for 
interaction<0.018; adjusted for age). Because the rate 
of myocardial scar was low in the lower 3 NT- proBNP 
categories for women, the lower 3 NT- proBNP catego-
ries were combined and served as the reference group 
in these analyses for women and men. Women in the 
highest quartile of NT- proBNP also had higher odds 
of having scar (odds ratio, 7.2; 95% CI, 2.1– 24.4; P 
<0.001) compared with those in the reference quartile 
after accounting for CVD risk factors (Table 5, model 
2), but no significant association was observed among 
men (Table 5, model 2). Of note, estimates for women 
were not as stable as those for other groups, as indi-
cated by the wide CIs, potentially attributable to small 
numbers of cases of myocardial scar in this group.
In stratified analyses, we found that the association 
between baseline NT- proBNP and risk of developing 
scar varied by myocardial scar groups (Table 6). This 
positive and significant association was also found for 
ischemic scar group (P- trend=0.04; Table  6, model 
2). No significant association was observed between 
baseline NT- proBNP levels and nonischemic scar.
Among the 113 participants with myocardial scar at 
year 10, the median total extent of scarring was 3.3% 
(interquartile range, 1.4– 7.2%). The average extent of 
myocardial scarring of ischemic scar was 9.0% (95% 
Table 3. 10- Year Changes in LV Structure/Function in Relation to Baseline NT- proBNP Quartiles (N=2416)
Models*
NT- proBNP Quartiles (pg/mL)
P Trend†
Q1 (Low, 5 to <24) 
N=704
Q2 (24 to <55) 
N=648
Q3 (55 to <112) 
N=608
Q4 (High, ≥112) 
N=456
Mean (95% CI)
Δ LV end- diastolic mass index, g/m2
Unadjusted 3.27 (2.55 to 3.98) 2.49 (1.75 to 3.24) 1.74 (0.97 to 2.50) 0.23 (−0.65 to 1.12)‖ <0.001
Model 1 2.52 (1.77 to 3.28) 2.45 (1.73 to 3.18) 2.13 (1.37 to 2.88) 0.91 (−0.02 to 1.84)§ 0.001
Model 2 1.92 (1.19 to 2.65) 2.38 (1.69 to 3.06) 2.16 (1.45 to 2.88) 1.90 (1.00 to 2.81) 0.399
Δ LV end- diastolic volume index, mL/m2
Unadjusted −4.50 (−5.39 to −3.61) −4.55 (−5.47 to −3.62) −4.69 (−5.64 to −3.73) −6.60 (−7.71 to −5.49)§ 0.001
Model 1 −4.81 (−5.77 to −3.85) −4.59 (−5.50 to −3.67) −4.48 (−5.44 to −3.52) −6.34 (−7.52 to −5.16)‡ 0.036
Model 2 −5.56 (−6.47 to −4.64) −4.78 (−5.63 to −3.92) −4.40 (−5.29 to −3.50) −5.02 (−6.15 to −3.89) 0.532
Δ LV end- systolic volume index, mL/m2
Unadjusted −1.61 (−2.16 to −1.06) −1.11 (−1.67 to −0.55) −1.01 (−1.59 to −0.43) −0.76 (−1.44 to −0.08)‡ 0.046
Model 1 −1.45 (−2.03 to −0.87) −1.14 (−1.69 to −0.58) −1.00 (−1.58 to −0.42) −0.98 (−1.70 to −0.27) 0.071
Model 2 −1.69 (−2.26 to −1.13) −1.23 (−1.77 to −0.70) −0.99 (−1.56 to −0.43) −0.47 (−1.18 to 0.23)§ 0.030
Δ LV stroke volume index, mL/m2
Unadjusted −3.40 (−4.06 to −2.74) −3.47 (−4.16 to −2.78) −3.47 (−4.18 to −2.76) −5.29 (−6.11 to −4.47)‖ 0.001
Model 1 −3.36 (−4.08 to −2.64) −3.45 (−4.14 to −2.76) −3.49 (−4.20 to −2.77) −5.35 (−6.24 to −4.47)‖ 0.002
Model 2 −4.12 (−4.74 to −3.50) −3.58 (−4.16 to −3.00) −3.34 (−3.95 to −2.74) −4.18 (−4.95 to −3.42) 0.890
Δ LV ejection fraction, %
Unadjusted −0.24 (−0.81 to 0.33) −0.63 (−1.20 to −0.05) −0.44 (−1.04 to 0.15) −1.69 (−2.39 to −0.99)§ 0.009
Model 1 −0.29 (−0.89 to 0.30) −0.59 (−1.16 to −0.01) −0.50 (−1.09 to 0.10) −1.60 (−2.34 to −0.87)§ 0.031
Model 2 −0.40 (−0.94 to 0.13) −0.53 (−1.03 to −0.03) −0.44 (−0.96 to 0.09) −1.60 (−2.26 to −0.94)§ 0.010
Δ Cardiac output, L/min
Unadjusted −0.43 (−0.57 to −0.29) −0.53 (−0.67 to −0.38) −0.39 (−0.54 to −0.24) −0.71 (−0.88 to −0.53)§ 0.047
Model 1 −0.45 (−0.60 to −0.30) −0.53 (−0.68 to −0.39) −0.38 (−0.53 to −0.23) −0.68 (−0.87 to −0.49) 0.181
Model 2 −0.45 (−0.58 to −0.32) −0.49 (−0.62 to −0.36) −0.45 (−0.58 to −0.32) −0.65 (−0.82 to −0.48) 0.068
All LV volume and mass measurements were adjusted for body surface area. Change (Δ) in LV structure/function was characterized by changes over 10 years 
from baseline to follow- up (year 10−baseline). CAC indicates coronary artery calcium; LV, left ventricular; and NT- proBNP, N- terminal pro- B- type natriuretic 
peptide.
*Model 1: adjusted for age, sex, and race (White [reference], African- American, Chinese, Hispanic); Model 2: adjusted for all variables in model 1 plus 
education more than high school, physical activity (sex- specific tertiles: low, middle, high), current cigarette smoking, diabetes mellitus, body mass index, 
systolic blood pressure, antihypertensive medication use, high- density lipoprotein cholesterol, total cholesterol, statin medication use, prevalence of CAC score 
>10, and baseline LV structure/function of outcome of interest.
†P for linear trend tested by entering log (NT- proBNP) as a continuous variable in the same model.
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CI, 6.7– 11.3), whereas that of nonischemic scar was 
3.2% (95% CI, 1.9– 4.5; P <0.001). Continuous per-
centage of LV scars were not investigated because 
of the low prevalence of scar in this relatively healthy 
adult cohort without concurrent overt diseases and 
the skewness of the data.
Additional Analyses
To assess the potential role of cardiovascular risk 
factor progression over time, adjustment for 10- year 
change in baseline cardiovascular risk factors were 
examined in additional analyses, and similar results 
were observed (data not shown). We also repeated 
the fully adjusted model for each outcome after ex-
cluding individuals with clinical CVD (myocardial 
infarction, resuscitated cardiac arrest, angina, con-
gestive heart failure, and stroke) between baseline 
and follow- up (N=126; 5.2% of the study population) 
and did not yield materially different results (data not 
shown).
DISCUSSION
In this longitudinal study of a cohort free of clinical CVD 
at baseline, we observed that elevated baseline NT- 
proBNP concentration was associated with significant 
Table 4. Global and Regional LV Strain and Dyssynchrony at Year 10 in Relation to NT- proBNP Quartiles (N=2211)
Models*
NT- proBNP Quartiles (pg/mL)
P Trend†
Q1 (Low, 5 to <24) 
N=641
Q2 (24 to <55) 
N=582
Q3 (55 to <112) 
N=564
Q4 (High, ≥112) 
N=424
Adjusted Mean (95% CI)
Peak systolic circumferential strain (ECC), %
Global
Model 1 −18.1 (−18.3 to −17.9) −18.1 (−18.3 to −17.9) −18.1 (−18.3 to −17.9) −18.0 (−18.2 to −17.8) 0.637
Model 2 −18.2 (−18.4 to −18.0) −18.1 (−18.3 to −17.9) −18.0 (−18.2 to −17.8) −17.9 (−18.2 to −17.7) 0.132
Basal
Model 1 −17.0 (−17.2 to −16.7) −16.9 (−17.2 to −16.7) −16.8 (−17.1 to −16.6) −16.4 (−16.8 to −16.3)‡ 0.106
Model 2 −17.0 (−17.2 to −16.8) −17.0 (−17.2 to −16.7) −16.7 (−17.0 to −16.5) −16.4 (−16.7 to −16.2)§ 0.014
Mid
Model 1 −18.1 (−18.3 to −17.9) −18.1 (−18.3 to −17.9) −18.2 (−18.4 to −17.9) −18.1 (−18.4 to −17.8) 0.746
Model 2 −18.1 (−18.4 to −17.9) −18.1 (−18.3 to −17.9) −18.1 (−18.3 to −17.9) −18.0 (−18.3 to −17.8) 0.716
Apical
Model 1 −19.3 (−19.5 to −19.0) −19.2 (−19.4 to −19.0) −19.2 (−19.4 to −19.0) −19.2 (−19.4 to −19.1) 0.965
Model 2 −19.3 (−19.5 to −19.1) −19.2 (−19.5 to −19.0) −19.2 (−19.5 to −19.0) −19.1 (−19.4 to −18.9) 0.046
Standard deviation of time to peak systolic circumferential strain, ms
Global
Model 1 3.7 (3.6 to 3.9) 3.8 (3.7 to 3.8) 3.8 (3.7 to 3.9) 3.9 (3.8 to 4.0)‡ 0.014
Model 2 3.7 (3.6 to 3.8) 3.8 (3.7 to 3.8) 3.8 (3.7 to 3.9) 3.9 (3.8 to 4.0)‡ 0.016
Basal
Model 1 3.6 (3.5 to 3.8) 3.6 (3.5 to 3.7) 3.6 (3.5 to 3.7) 3.7 (3.6 to 3.9) 0.447
Model 2 3.7 (3.5 to 3.8) 3.6 (3.5 to 3.7) 3.6 (3.5 to 3.7) 3.7 (3.5 to 3.9) 0.758
Mid
Model 1 3.6 (3.5 to 3.7) 3.6 (3.4 to 3.7) 3.6 (3.5 to 3.7) 3.7 (3.5 to 3.9) 0.080
Model 2 3.6 (3.5 to 3.7) 3.6 (3.4 to 3.7) 3.6 (3.5 to 3.7) 3.7 (3.5 to 3.8) 0.043
Apical
Model 1 3.3 (3.2 to 3.4) 3.4 (3.3 to 3.5) 3.4 (3.3 to 3.6) 3.4 (3.2 to 3.5) 0.073
Model 2 3.3 (3.2 to 3.4) 3.4 (3.3 to 3.5) 3.4 (3.3 to 3.6) 3.5 (3.3 to 3.6)‡ 0.041
ECC denotes circumferential shortening and is normally negative; less negative values of ECC reflect decreased regional function. CAC, coronary artery 
calcium; LV, left ventricular; and NT- proBNP, N- terminal pro- B- type natriuretic peptide.
*Model 1: adjusted for age, sex, and race (White [reference], African- American, Chinese, Hispanic); Model 2: adjusted for all variables in model 1 plus 
education more than high school, physical activity (sex- specific tertiles: low, middle, high), current cigarette smoking, diabetes mellitus, body mass index, 
systolic blood pressure, antihypertensive medication use, high- density lipoprotein cholesterol, total cholesterol, statin medication use, prevalence of CAC score 
>10, and LV mass.
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longitudinal decrease in LVEF, more severe cardiac 
dyssynchrony, and higher odds of developing myocar-
dial scar.
Our findings that higher baseline NT- proBNP levels 
are significantly associated with lower LVEF, and more 
residual blood at end systole over 10- year follow- up 
reflect a possible increase in LV filling pressure, a 
marker of diastolic dysfunction. A positive association 
between high BNP (B- type natriuretic peptide) levels 
and diastolic LV filling pressure has been reported pre-
viously in patients with recent myocardial infarction.18 
In a community- based cohort of individuals free of 
heart failure, diastolic dysfunction was more common 
among those with greater BNP levels.19 Furthermore, 
increased BNP levels were previously suggested to 
serve as the hallmark of diastolic heart failure indepen-
dent of LV hypertrophy.20
Association of NT- proBNP with diastolic dysfunc-
tion is also reported in a cross- sectional study of the 
MESA cohort3 that showed elevated log– NT- proBNP 
is related to increment of native T1 and extracellu-
lar volume fraction, imaging markers of microscopic 
myocardial fibrosis that play a crucial role in the de-
velopment of diastolic dysfunction. These results 
suggest that increased fibrosis leads to decreased 
LV relaxation, increased stiffness, and elevated LV 
filling pressures, with a subsequent increase in NT- 
proBNP levels.
Previously, Wang et al2 reported in participants 
without heart failure from the Framingham study a sig-
nificant increase in the risk of death, first cardiovas-
cular event, heart failure, atrial fibrillation, and stroke 
with increase in log- BNP level during a mean follow- up 
of 5.2  years. Moreover, it was previously shown that 
a single measure of NT- proBNP predicts incidence of 
heart failure in asymptomatic individuals beyond tradi-
tional cardiovascular risk factors and LV hypertrophy in 
a multiethnic population.21
Our study was conducted among a relatively health-
ier cohort of adults without prevalent CVD at baseline. 
Table 5. Risk of Myocardial Scar at Year 10 in Relation to Baseline NT- proBNP Quartiles, Total and by Sex
Models*
NT- proBNP Quartiles (pg/mL)
P Trend†
Q1 (5 to <24) 
Reference Q2 (24 to <55) Q3 (55 to <112) Q4 (≥112)
Odds Ratio (95% CI)‡
Total myocardial scar
No. of cases/total (113/1498) 30/492 30/406 24/358 29/242
Unadjusted 1.0 1.2 (0.7– 2.1) 1.1 (0.6– 1.9) 2.1 (1.2– 3.6)‖ 0.018
Model 1 1.0 1.3 (0.8– 2.3) 1.3 (0.7– 2.5) 2.9 (1.5– 5.6)¶ 0.003
Model 2 1.0 1.3 (0.7– 2.2) 1.2 (0.6– 2.3) 2.7 (1.4– 5.5)‖ 0.012
Lower 3 quartiles combined (5 to <112)# 
Reference Q4 (≥112) P Trend†
Women
No. of cases /total (16/708) 5/535 11/173
Unadjusted 1.0 7.2 (2.4– 21.0)¶ <0.001
Model 1 1.0 6.9 (2.2– 21.0)¶ <0.001
Model 2 1.0 7.2 (2.1– 24.4)¶ 0.001
Men
No. of cases/total (97/790) 79/721 18/69
Unadjusted 1.0 2.9 (1.6– 5.1) <0.001
Model 1 1.0 1.7 (0.9– 3.1) 0.109
Model 2 1.0 1.8 (0.9– 3.5) 0.101
Association of NT- proBNP with risk of scar differed by sex (P for interaction=0.018; adjusted for age). NT- proBNP indicates N- terminal pro- B- type natriuretic 
peptide.
*Model 1: adjusted for age, sex (total only), and race (White [reference], African- American, Chinese, Hispanic); Model 2: adjusted for all variables in model 
1 plus education more than high school, physical activity (sex- specific tertiles: low, middle, high), current cigarette smoking, diabetes mellitus, body mass 
index, systolic blood pressure, antihypertensive medication use, high- density lipoprotein cholesterol, total cholesterol, statin medication use, and prevalence 
of coronary artery calcium score >10.
†P for linear trend tested by entering log (NT- proBNP) as a continuous variable in the same model.
‡Odds ratio represents the odds of having scar at year 10 in the NT- proBNP quartile relative to the reference category, adjusting for all other covariates in 
the model.
‖ P<0.01, ¶P <0.001 for comparisons between the highest quartile relative to the reference category.
#Because the rate of myocardial scar was low in the lower 3 NT- proBNP categories in women, the lower 3 NT- proBNP categories were combined and served 
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Although the overall prevalence of myocardial scar at 
year 10 was low in our study (7.5%) compared with other 
higher- risk cohorts, the association of NT- proBNP lev-
els with risk of myocardial scar was positive, significant, 
and graded. In a previous MESA study, the prevalence 
of myocardial scar was reported 7.9% at year 10, while 
78% of these participants were unrecognized by ECG 
or clinical assessment.7 In the ICELAND study,22 in el-
derly participants, the prevalence of recognized and 
unrecognized myocardial scar detected by CMR were 
9.7% and 17%, respectively. After adjustment for risk 
factors, unrecognized myocardial scar remained asso-
ciated with mortality,22 emphasizing the importance of 
early identification of patients with myocardial scar. We 
found that the higher chance of developing myocardial 
scar is sex specific, and in women, higher NT- proBNP 
level was associated with higher odds of myocardial 
scar at year 10. This is in keeping with prior findings 
from a MESA study, which reported that a higher ex-
tent of dyssynchrony in women but not in men pre-
dicted major adverse cardiovascular events, including 
myocardial infarction, heart failure, stroke, and death.23
Our results further support the concept that how NT- 
proBNP is related to cardiovascular events or death re-
ported in prior community- based studies.2,24 Elevated 
NT- proBNP levels are related to a higher chance of 
developing macroscopic scar over time as seen in our 
study, as well as having microscopic scar (indicated 
by high native T1 and extracellular volume fraction 
values) as reported in another cross- sectional MESA 
study.3 The mechanism of involvement of NT- proBNP 
in CVD was not well understood. Replacement of via-
ble myocardial tissue with fibrotic noncontractile tissue 
can subsequently result in decreased LVEF and ECC, 
less synchronized myocardial contraction, or more se-
vere dyssynchrony and a higher chance of arrythmia, 
which all predisposes the patients to a higher risk of 
major cardiovascular events or death. These results 
further reiterate the importance of prior suggestions 
that measurement of NT- proBNP can be part of the 
patient’s evaluation and help to establish the diagnosis 
and prognosis of heart failure in outpatient settings.25
NT- proBNP is the metabolically inactive cleav-
age product of the prohormone proBNP. The active 
hormone BNP was not measured in MESA, but pre-
vious studies have shown that inactive NT- proBNP 
is believed to be secondary to increased myocardial 
stretch.26 The significant association between higher 
baseline NT- proBNP levels and smaller decline in LV 
end- systolic volume over 10- year follow- up seen here 
means more residual blood at end systole, which can 
cause increased myocardial stretch and subsequently 
triggers synthesis of proBNP. Elevated BNP levels were 
related to cardiac geometric remodeling and increas-
ing sphericity indices, and a lower LVEF in patients with 
stable chronic ischemic cardiomyopathy.27 Higher NT- 
proBNP concentrations were also significantly associ-
ated with larger infarct size and lower LVEF in patients 
Table 6. Risk of Myocardial Scar at Year 10 in Relation to Baseline NT- proBNP Quartiles, by Myocardial Scar Groups
Models*
NT- proBNP Quartiles (pg/mL)
P Trend†
Q1 (5 to <24) 
Reference Q2 (24 to <55) Q3 (55 to <112) Q4 (≥112)
Odds Ratio (95% CI)‡
Ischemic scar
No. of cases/total 
(51/1498)
13/492 8/406 14/358 16/242
Unadjusted 1.0 0.7 (0.3– 1.8) 1.5 (0.7– 3.2) 2.6 (1.2– 5.5)‖ 0.006
Model 1 1.0 0.7 (0.3– 1.8) 1.6 (0.7– 3.6) 2.8 (1.2– 6.9)§ 0.013
Model 2 1.0 0.7 (0.3– 1.7) 1.3 (0.6– 3.2) 2.5 (1.1– 6.8)§ 0.040
Nonischemic scar
No. of cases/total 
(62/1498)
17/492 22/406 10/358 13/242
Unadjusted 1.0 1.6 (0.8– 3.1) 0.8 (0.4– 1.8) 1.6 (0.8– 3.3) 0.494
Model 1 1.0 1.8 (0.9– 3.6) 1.1 (0.5– 2.5) 2.3 (1.0– 5.5)§ 0.103
Model 2 1.0 1.8 (0.9– 3.7) 1.0 (0.4– 2.4) 2.3 (0.9– 5.9) 0.148
NT- proBNP indicates N- terminal pro- B- type natriuretic peptide.
*Model 1: adjusted for age, sex, and race (White [reference], African- American, Chinese, Hispanic); Model 2: adjusted for all variables in model 1 plus 
education more than high school, physical activity (sex- specific tertiles: low, middle, high), current cigarette smoking, diabetes mellitus, body mass index, 
systolic blood pressure, antihypertensive medication use, high- density lipopeotein cholesterol, total cholesterol, statin medication use, and prevalence of 
coronary artery calcium score >10.
†P for linear trend tested by entering log (NT- proBNP) as a continuous variable in the same model.
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with ST elevation myocardial infarction.28 Reduced 
myocardial perfusion was also associated with in-
creased NT- proBNP in a cross- sectional MESA study, 
which probably reflects microvascular dysfunction,1 
and presence of fibrotic tissue needless of blood flow. 
Elevated baseline NT- proBNP and its significant asso-
ciation with more severe dyssynchrony seen in our 10- 
year follow- up may indicate changes in both regional 
and global cardiac contractility, which are likely sec-
ondary to underlying fibrosis. Moreover, NT- proBNP is 
reported to be strongly associated with the incidence 
of atrial fibrillation in a population- based cohort.9
The association of NT- proBNP with impaired 
ECC and more severe dyssynchrony is important. 
Development of dyssynchrony can be used as the 
surrogate of asymptomatic LV function impairment, 
since alterations in the synchronization of LV myocar-
dial contraction precede impairment in global LV func-
tion.16 Inverse association of myocardial perfusion at 
rest with greater extent of myocardial dyssynchrony 
and increased time to peak systolic deformation has 
been reported previously in a MESA study.6 Moreover, 
in asymptomatic individuals, lower myocardial flow re-
serve was correlated with reduced regional function, 
expressed as lower ECC.29 Even in patients with prior 
myocardial infarction, although LV scar burden was as-
sociated with the occurrence of ventricular tachycardia 
during follow- up, but LV dyssynchrony was shown to 
be independently correlated with occurrence of ven-
tricular tachycardia.30
Figure. Flow diagram characteristics of MESA participants who contributed to each of 
the analysis cohorts evaluating the relationships between NT- proBNP and baseline LV 
parameters, change in LV parameters over time, LV dyssynchrony/strain parameters, and 
having myocardial scar over time.
Renal dysfunction=estimated glomerular filtration rate of less than 45 mL/min per 1.73 m2. CMR 
indicates cardiac magnetic resonance imaging; LGE, late gadolinium enhancement; LV, left 
ventricular; MESA, Multi- Ethnic Study of Atherosclerosis; and NT- proBNP, N- terminal pro- B- type 
natriuretic peptide.
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We found that individuals with elevated NT- 
proBNP levels had higher odds of having myocardial 
scar and systolic and possibly diastolic function im-
pairment independent of traditional CVD risk factors. 
Our results further support the hypothesis that both 
systolic and diastolic dysfunction represent devel-
opment of myocardial mechanical impairment, and 
both are likely present in varying degrees in patients 
with heart failure.6
Our longitudinal analysis may have been subject 
to selection bias by limiting analyses to individuals 
who were able to complete both the baseline and fol-
low- up CMR. The baseline characteristics of MESA 
participants included in this analysis demonstrated 
a healthier cohort compared with those excluded. 
However, we do not believe selection bias would alter 
the longitudinal results qualitatively. If selection bias 
was absent and if the study cohort was less healthy, 
we would expect to observe directionally similar NT- 
proBNP– related longitudinal changes in LV structure/
function, dyssynchrony, and development of myo-
cardial scar to an even greater degree than what we 
observed.
Strengths and Limitations
The strengths of our study include the ability to 
conduct longitudinal analyses relating baseline 
NT- proBNP levels to change in CMR- assessed LV 
structure/function, dyssynchrony, and developing of 
myocardial scar in a well- characterized, multiethnic 
cohort, after adjustment for baseline traditional CVD 
risk factors and CVD risk factor progression over 
time.
Our study was subject to some limitations. Although 
we were able to adjust for several covariates given 
our large sample size, residual confounding is an 
issue that cannot be ruled out in observational study. 
Furthermore, the use of correction equations to ac-
count for differences in CMR pulse sequence technol-
ogy and software that occurred between baseline and 
year 10 to make the data comparable may have also 
contributed some measurement errors. Although not a 
limitation per se, the MESA cohort was free of clinical 
CVD at baseline, our findings cannot be extrapolated 
to individuals with symptoms or known coronary artery 
disease.
CONCLUSIONS
Among people without prevalent CVD, a higher level 
of NT- proBNP was prospectively associated with 
development of subclinical changes in developing 
myocardial dysfunction, more severe myocardial dys-
synchrony, and higher odds of developing myocardial 
scar independent of established cardiovascular risk 
factors. More importantly, our findings lend support to 
consider earlier screening using biomarkers such as 
NT- proBNP in identifying people with subclinical CVD 
who may benefit most from early therapeutic interven-
tion and provide measures for CVD prevention.
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At baseline (2000-2002), cardiac function and volumes were calculated from short-axis cine 
images from fast gradient echo (FGRE) CMR pulse sequence using MASS software (version 4.2, 
Medic, Leiden, the Netherlands). At year 10 (2010-2012, follow-up), endocardial and epicardial 
borders of the LV were determined from steady state free precession (SSFP) cine images using 
the CIM software (version 6.2, Auckland MRI Research Group, University of Auckland, New 
Zealand).  Reflecting changes in clinical CMR technology that has occurred since the baseline 
exam, the CMR follow-up protocol used a different pulse sequence (SSFP) than that of the 
baseline exam (FGRE). SSFP allows faster imaging exams with higher image quality but 
produces different LV volumes and mass than FGRE. 31, 32  In addition, the follow-up exam used 
different imaging readers and incorporated advances in analysis software.  
To adjust for these differences, two calibration curves were sequentially applied to each 
participant’s baseline LV mass and volume measurements: one curve to correct for potential 
reader-software differences and one to correct for potential pulse sequence differences.  The 
latter also corrects for scanner equipment differences between baseline and follow-up exams. To 
provide data for these calibration curves, 498 participants were randomly chosen to form a 
calibration group that underwent FGRE and SSFP MRI during the follow-up exam.  In selecting 
this group, body surface area quintiles were equally sampled so that subsequent calibration 
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Data from the calibration group was used to construct two calibration curves as follows.  MESA 
Year 10 imaging readers re-analyzed the calibration group’s MESA baseline CMR data using 
MESA Year 10 software (CIM) and reading protocols.  The reader-software calibration curves 
were constructed by plotting these readings against the MESA baseline measurements.  The 
MESA Year-10 readers also used CIM to analyze the calibration group’s MESA Year 10 FGRE 
images.  The pulse sequence calibration curves were constructed by plotting these FGRE 
readings against the main SSFP measurements by the same readers.  Calibration curves were 
found to be linear and fitted with ordinary regression methods. A detailed explanation of the 
development and application of calibration curves are presented in the Supplemental CMR 
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Table S1. Baseline Characteristics of Study Participants Compared with Individuals 








Age,  mean (SD), y  59.6 (9.3) 64.7 (10.7) <0.001 
Women, N (%) 1235 (51.1) 854 (51.0) 0.933 
Race/ethnicity, N (%)    




 African-American 532 (22.0) 404 (24.1) 
 Hispanic 510 (21.1) 439 (26.2) 
 Chinese 331 (13.7) 262 (15.6) 
NT-proBNP, median (IQR), pg/mL 46.9 (20.5 - 91.9) 63.6 (28.7 – 137.9) <0.001 
    
Education > HS graduate, N (%)  1723 (71.3) 957 (57.1) <0.001 
BMI, mean (SD), kg/m2 27.6 (4.9) 27.7 (5.0) 0.409 
Smoking status, N (%)    
 Never 1283 (53.1) 849 (50.7)  
0.045 
 
 Former 867 (35.9) 600 (35.8) 
 Current 266 (11.0) 226 (13.5) 
Physical activity†, median (IQR), MET-
min/week 
945.0 
(210.0 – 2100.0) 
787.5 
(0.0 – 1972.5) 
0.001 
    
Systolic BP, mean (SD), mmHg 122.9 (20.0) 129.0 (22.7) <0.001 
Diastolic BP, mean (SD), mmHg 71.7 (10.2) 71.8 (10.4) 0.668 
Heart rate, mean (SD), beats/min 62.3 (9.1) 63.4 (9.9) <0.001 
Anti-hypertensive medication, N (%) 739 (30.6) 693 (41.4) <0.001 
Diabetes, N (%) 201 (8.3) 262 (15.6) <0.001 
HDL-C cholesterol, mean (SD), mg/dL 51.3 (14.8) 51.0 (14.9) 0.548 
Total cholesterol, mean (SD), mg/dL 193.6 (33.9) 194.3 (35.5) 0.503 
Statin medication, N (%) 326 (13.5) 254 (15.2) <0.001 
CAC score > 10, N (%), Agatston units 863 (36.0) 847 (50.6) <0.001 
    
Left ventricle, mean (SD)    
 End diastolic mass index, g/m2 64.2 (11.2) 65.7 (12.8) <0.001 
 End diastolic volume index, mL/m2 69.9 (12.1) 69.1 (13.7) 0.069 
 End systolic volume index, mL/m2 26.1 (6.4) 26.1 (7.8) 0.907 
 Stroke volume index, ml/m2 43.8 (8.4) 43.0 (9.1) 0.006 
 Ejection fraction, % 62.7 (5.8) 62.3 (6.6) 0.061 
Cardiac output, mean (SD), L/min 5.3 (1.4) 5.7 (1.5) <0.001 
    
Results are expressed as mean (SD), number (%), or median (IQR). All LV volume and mass measurements were 
adjusted for body surface area.  NT-proBNP indicates N-terminal pro-brain natriuretic peptide; SD, standard 
deviation; HS, high school; IQR, Interquartile range (Q1-Q3); BMI, body mass index; BP, blood pressure; HDL, 
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†Includes moderate walking exercise, dance and vigorous sports.  § P values for test of difference between included 
compared with those excluded; unpaired t test for continuous variables, Chi-square, or McNemar for categorical 
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Table S2. Pearson Correlations Between Log (NT-proBNP) Levels and Baseline Risk 
Factors. 




Age (per y)  0.386 <0.001 
Sex (male vs female) -0.347 <0.001 
Race/ethnicity   
 African-American vs White -0.095 <0.001 
 Hispanic vs White -0.056 0.005 
 Chinese vs White -0.118 <0.001 
Education > HS graduate vs Education < HS  -0.048 0.017 
BMI (kg/m2) -0.067 <0.001 
Current smokers vs Never/Former smokers -0.048 0.016 
Physical activity (sex-specific tertiles, MET-min/week) †   
 Middle vs Low 0.009 0.663 
 High vs Low 0.048 0.017 
Systolic BP (mmHg) 0.214 <0.001 
Anti-hypertensive medication user vs Nonusers 0.163 <0.001 
Diabetic vs Non-diabetic -0.059 0.003 
HDL-C cholesterol (mg/dL) 0.254 <0.001 
Total cholesterol (mg/dL) -0.020 0.325 
Statin medication user vs Nonusers 0.010 0.611 
CAC score > 10 vs CAC score < 10 0.102 <0.001 
   
NT-proBNP, N-terminal pro-brain natriuretic peptide; HS, high school; BMI, body mass index; BP, blood 
pressure; HDL, high-density lipoprotein; CAC, Coronary Artery Calcium; MET, metabolic equivalent of 
task. 
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